BCMA-Targeted T-Cell Engager Therapy for Refractory Pemphigus

This case report describes 2 patients with pemphigus and off-label teclistamab use.

Corresponding Authors: Moritz Ronicke, MD, Department of Dermatology (moritz.ronicke@uk-erlangen.de), and Ricardo Grieshaber-Bouyer, MD, Department of Medicine 3–Rheumatology and Immunology (ricardo.grieshaber@fau.de), Uniklinikum Erlangen, Ulmenweg 18, 91054 Erlangen, Germany.

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.